Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prudence Ive

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
The Journal of Infectious Diseases|March 27, 2012
Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan AfricaKim C E Sigaloff, Raph L Hamers, Carole L Wallis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2012
Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategiesRaph L Hamers, Kim C E Sigaloff, Annemarie M Wensing, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter StudiesRodolphe Thiébaut, Ana Jarne, Jean-Pierre Routy, et al.
Lancet (London, England)|June 19, 2010
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trialIan Sanne, Catherine Orrell, Matthew P Fox, et al.
Scientific Reports|October 27, 2018
Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistanceSeth C Inzaule, Cissy M Kityo, Margaret Siwale, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2012
Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countriesKim C E Sigaloff, Raph L Hamers, Jack Menke, et al.
The Lancet. Infectious Diseases|November 1, 2011
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort studyRaph L Hamers, Rob Schuurman, Kim C E Sigaloff, et al.
AIDS (London, England)|July 18, 2020
The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan AfricaSeth C Inzaule, Silvia Bertagnolio, Cissy M Kityo, et al.
AIDS (London, England)|May 24, 2022
Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysisSeth C Inzaule, Stefanie Kroeze, Cissy M Kityo, et al.
The Journal of Infectious Diseases|February 16, 2010
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infectionDavid A Cooper, Jayvant Heera, James Goodrich, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
The Journal of Infectious Diseases|March 27, 2012
Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan AfricaKim C E Sigaloff, Raph L Hamers, Carole L Wallis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2012
Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategiesRaph L Hamers, Kim C E Sigaloff, Annemarie M Wensing, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter StudiesRodolphe Thiébaut, Ana Jarne, Jean-Pierre Routy, et al.
Lancet (London, England)|June 19, 2010
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trialIan Sanne, Catherine Orrell, Matthew P Fox, et al.
Scientific Reports|October 27, 2018
Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistanceSeth C Inzaule, Cissy M Kityo, Margaret Siwale, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2012
Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countriesKim C E Sigaloff, Raph L Hamers, Jack Menke, et al.
The Lancet. Infectious Diseases|November 1, 2011
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort studyRaph L Hamers, Rob Schuurman, Kim C E Sigaloff, et al.
AIDS (London, England)|July 18, 2020
The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan AfricaSeth C Inzaule, Silvia Bertagnolio, Cissy M Kityo, et al.
AIDS (London, England)|May 24, 2022
Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysisSeth C Inzaule, Stefanie Kroeze, Cissy M Kityo, et al.
The Journal of Infectious Diseases|February 16, 2010
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infectionDavid A Cooper, Jayvant Heera, James Goodrich, et al.
Pageof 5